Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 82Leukemia, Myeloid, Acute 63Leukemia, Myelomonocytic, Chronic 31Leukemia 21Myeloproliferative Disorders 15Primary Myelofibrosis 9Thrombocythemia, Essential 7Polycythemia Vera 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Blast Crisis 7Myelodysplastic-Myeloproliferative Diseases 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Recurrence 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Biphenotypic, Acute 4Anemia, Refractory, with Excess of Blasts 4Anemia, Refractory 4Leukemia, Monocytic, Acute 3Congenital Abnormalities 3Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Preleukemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

decitabine and cedazuridine drug combination 1Injections 1Decitabine 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Accelerated Phase Myeloproliferative Neoplasm × Decitabine × Myeloid × Clear all
NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
27 enrolled
Myeloid

Accelerated Phase Myeloproliferative Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡